1. Bay-117082 treats sepsis by inhibiting neutrophil extracellular traps (NETs) formation through down-regulating NLRP3/N-GSDMD.
- Author
-
Zou S, Han X, Luo S, Tan Q, Huang H, Yao Z, Hou W, Jie H, and Wang J
- Subjects
- Animals, Mice, Acute Lung Injury immunology, Acute Lung Injury pathology, Male, Mice, Inbred C57BL, Humans, Neutrophils immunology, Down-Regulation, Cytokines metabolism, Bronchoalveolar Lavage Fluid immunology, Bronchoalveolar Lavage Fluid cytology, Disease Models, Animal, Gasdermins, Extracellular Traps immunology, Extracellular Traps metabolism, Sepsis immunology, Sepsis metabolism, NLR Family, Pyrin Domain-Containing 3 Protein metabolism, Sulfones pharmacology, Sulfones therapeutic use, Nitriles pharmacology, Intracellular Signaling Peptides and Proteins metabolism, Intracellular Signaling Peptides and Proteins genetics, Phosphate-Binding Proteins metabolism, Phosphate-Binding Proteins genetics
- Abstract
During the inflammatory storm of sepsis, a significant quantity of neutrophil extracellular traps (NETs) are generated, which act as a double-edged sword and not only impede the invasion of foreign microorganisms but also exacerbate organ damage. This study provides evidence that NETs can cause damage to alveolar epithelial cells in vitro. The sepsis model developed in this study showed a significant increase in NETs in the bronchoalveolar lavage fluid (BALF). The development of NETs has been shown to increase the lung inflammatory response and aggravate injury to alveolar epithelial cells. Bay-117082, a well-known NF-κB suppressor, is used to modulate inflammation. This analysis revealed that Bay-117082 efficiently reduced total protein concentration, myeloperoxidase activity, and inflammatory cytokines in BALF. Moreover, Bay-117082 inhibited the formation of NETs, which in turn prevented the activation of the pore-forming protein gasdermin D (GSDMD). In summary, these results indicated that excessive NET production during sepsis exacerbated the onset and progression of acute lung injury (ALI). Therefore, Bay-117082 could serve as a novel therapeutic approach for ameliorating sepsis-associated ALI., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF